Scil Proteins GmbH / Navigo Proteins

Activities: Manufacturing Ingredients Research & Development Pharmaceutical

Trending Articles

  1. Wacker Biotech to manufacture protein ingredients for MinervaX's late-stage GBS vaccine The vaccine is currently being prepared for Phase III trials, and aims to protect mothers and their babies from group B streptococcus infections
  2. Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
  3. AstraZeneca opens a 'people hub' at its Macclesfield site The energy-efficient building will offer AZ employees a collaborative space
  4. Ensuring cGMP compliance in cell and gene therapy manufacturing 3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
  5. Piramal Pharma's sustainability goals get SBTi-validated The company wants to reduce its scope 1 and 2 GHG emissions by 42% by 2030, and is also working on developing a carbon reduction plan

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Media

UV-Cap acquires 100% shares of Scil Proteins

Scil Proteins is acquired from Bionet Ventures and renamed Navigo Proteins
Research & Development

ITM and Scil Proteins agree targeted radio conjugates partnership

German firms will develop targeted radio conjugates for imaging and therapy purposes, in a variety of indications
Manufacturing

Wacker acquires Scil Proteins Production

The transaction will create a leading microbial-based biopharmaceutical manufacturer
Ingredients

Scil Proteins receives EMA approval for commercial production of Reteplase

The recombinant protein will be produced in Halle, Germany
Research & Development

Rainer-Rudolph-Foundation acknowledges outstanding research

Awards three prizes to young researchers in the fields of protein biochemistry and biotechnology
Ingredients

Scil Proteins establishes business development organisation in California

To be headed by Garry Merry
Pharmaceutical

Call for entries to Rainer Rudolph Foundation prizes

Closing date is 31 March
Subscribe now